NEW YORK, October 28, 2025 – Proskauer is proud to share that Litigation partner Fangli Chen, Ph.D. has been named to IAM’s 2026 list of Global Leaders for the fifth consecutive year. The annual honor recognizes some of the world’s leading patent professionals.
Fangli is a distinguished patent attorney known for her strategic foresight and exceptional problem-solving skills. As chair of Proskauer’s Life Sciences Patent Practice, she represents a diverse range of biotech and pharmaceutical companies and specializes in the strategic development of complex IP portfolios. Fangli’s practice also focuses on post-grant review before the USPTO, oppositions, pre-litigation and litigation strategy, due diligence investigations, freedom-to-operate, non-infringement and invalidity analysis, licensing and other IP matters in commercial transactions.
Earlier this year, Fangli was named to the IAM Patent 1000, the annual directory that identifies the top law firms and attorneys in the world’s most significant patent jurisdictions. Selection for IAM Global Leaders is limited to those ranked in the IAM Patent 1000 who innovate, inspire and go above and beyond to deliver value for their clients.
Read the full list of
About Proskauer
The world’s leading organizations and global players choose Proskauer to represent them when they need it the most. With 800+ lawyers in key financial centers around the world, we are highly regarded for our expertise combined with our pragmatic and commercial approach. Proskauer is the place to turn when a matter is complex, innovative and game-changing. We work seamlessly across practices, industries and jurisdictions with asset managers, private equity and venture capital firms, Fortune 500 and FTSE companies, major sports leagues, entertainment industry legends and other industry-redefining companies.
Our sophisticated patent team provides strategic value at every stage of the patent development and protection process. Renowned for delivering exceptional results, we assist our clients in patent litigation, portfolio development, licensing, technology transfer and strategic counseling. We are among the few major firms that excel in plaintiffs' side portfolio work, litigation and licensing, consistently delivering exceptional results.